Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors.

Cantey PT, Stramer SL, Townsend RL, Kamel H, Ofafa K, Todd CW, Currier M, Hand S, Varnado W, Dotson E, Hall C, Jett PL, Montgomery SP.

Transfusion. 2012 Sep;52(9):1922-30. doi: 10.1111/j.1537-2995.2012.03581.x. Epub 2012 Mar 8.

PMID:
22404755
2.

Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease.

Machado FS, Dutra WO, Esper L, Gollob KJ, Teixeira MM, Factor SM, Weiss LM, Nagajyothi F, Tanowitz HB, Garg NJ.

Semin Immunopathol. 2012 Nov;34(6):753-70. doi: 10.1007/s00281-012-0351-7. Epub 2012 Oct 18. Review.

3.

Proteome expression and carbonylation changes during Trypanosoma cruzi infection and Chagas disease in rats.

Wen JJ, Garg NJ.

Mol Cell Proteomics. 2012 Apr;11(4):M111.010918. doi: 10.1074/mcp.M111.010918. Epub 2011 Dec 22.

4.

Role of PPARs in Trypanosoma cruzi Infection: Implications for Chagas Disease Therapy.

Hovsepian E, Penas F, Mirkin GA, Goren NB.

PPAR Res. 2012;2012:528435. doi: 10.1155/2012/528435. Epub 2012 Feb 9.

5.

Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease.

Brener Z, Gazzinelli RT.

Int Arch Allergy Immunol. 1997 Oct;114(2):103-10. Review.

PMID:
9338602
6.

A DNA vaccine encoding for TcSSP4 induces protection against acute and chronic infection in experimental Chagas disease.

Arce-Fonseca M, Ramos-Ligonio A, López-Monteón A, Salgado-Jiménez B, Talamás-Rohana P, Rosales-Encina JL.

Int J Biol Sci. 2011;7(9):1230-8. Epub 2011 Oct 25.

7.

Infection and invasion mechanisms of Trypanosoma cruzi in the congenital transmission of Chagas' disease: a proposal.

Kemmerling U, Bosco C, Galanti N.

Biol Res. 2010;43(3):307-16. doi: /S0716-97602010000300007. Epub 2010 Nov 30. Review.

8.

Infection-associated vasculopathy in experimental chagas disease pathogenic roles of endothelin and kinin pathways.

Scharfstein J, Andrade D.

Adv Parasitol. 2011;76:101-27. doi: 10.1016/B978-0-12-385895-5.00005-0. Review.

PMID:
21884889
9.

Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic.

Pinazo MJ, Cañas E, Elizalde JI, García M, Gascón J, Gimeno F, Gomez J, Guhl F, Ortiz V, Posada Ede J, Puente S, Rezende J, Salas J, Saravia J, Torrico F, Torrus D, Treviño B.

Gastroenterol Hepatol. 2010 Mar;33(3):191-200. doi: 10.1016/j.gastrohep.2009.07.009. Epub 2009 Oct 17. Review. No abstract available.

PMID:
19837482
10.

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

Doyle PS, Chen CK, Johnston JB, Hopkins SD, Leung SS, Jacobson MP, Engel JC, McKerrow JH, Podust LM.

Antimicrob Agents Chemother. 2010 Jun;54(6):2480-8. doi: 10.1128/AAC.00281-10. Epub 2010 Apr 12.

11.

[Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic].

Gascón J, Albajar P, Cañas E, Flores M, Gómez i Prat J, Herrera RN, Lafuente CA, Luciardi HL, Moncayo A, Molina L, Muñoz J, Puente S, Sanz G, Treviño B, Sergio-Salles X.

Rev Esp Cardiol. 2007 Mar;60(3):285-93. Review. Spanish.

12.

Chronic indeterminate phase of Chagas' disease: mitochondrial involvement in infection with two strains.

Báez AL, Lo Presti MS, Fretes R, Díaz C, Pons P, Bazán PC, Strauss M, Rivarola HW, Paglini-Oliva P.

Parasitology. 2013 Mar;140(3):414-21. doi: 10.1017/S0031182012001771. Epub 2012 Nov 9.

PMID:
23137884
13.

Maternal infection with Trypanosoma cruzi and congenital Chagas disease induce a trend to a type 1 polarization of infant immune responses to vaccines.

Dauby N, Alonso-Vega C, Suarez E, Flores A, Hermann E, Córdova M, Tellez T, Torrico F, Truyens C, Carlier Y.

PLoS Negl Trop Dis. 2009 Dec 22;3(12):e571. doi: 10.1371/journal.pntd.0000571.

14.

[Transmission of chagasic infection by oral route in the natural history of Chagas disease].

Coura JR.

Rev Soc Bras Med Trop. 2006;39 Suppl 3:113-7. Portuguese.

PMID:
17605219
15.

Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection).

Reyes PA, Vallejo M.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004102. Review.

PMID:
16235350
16.

Identification of blood meal source and infection with Trypanosoma cruzi of Chagas disease vectors using a multiplex cytochrome b polymerase chain reaction assay.

Mota J, Chacon JC, Gutiérrez-Cabrera AE, Sánchez-Cordero V, Wirtz RA, Ordoñez R, Panzera F, Ramsey JM.

Vector Borne Zoonotic Dis. 2007 Winter;7(4):617-27.

PMID:
18021027
17.

Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-gamma, TNF-alpha, and low IL-10 production during the acute infection phase.

Guedes PM, Veloso VM, Afonso LC, Caliari MV, Carneiro CM, Diniz LF, Marques-da-Silva EA, Caldas IS, Do Valle Matta MA, Souza SM, Lana M, Chiari E, Galvão LM, Bahia MT.

Vet Immunol Immunopathol. 2009 Jul 15;130(1-2):43-52. doi: 10.1016/j.vetimm.2009.01.004. Epub 2009 Jan 23.

PMID:
19211152
18.

A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.

Doyle PS, Zhou YM, Engel JC, McKerrow JH.

Antimicrob Agents Chemother. 2007 Nov;51(11):3932-9. Epub 2007 Aug 13.

19.

Mouse model for Chagas disease: immunohistochemical distribution of different stages of Trypanosoma cruzi in tissues throughout infection.

Guarner J, Bartlett J, Zaki SR, Colley DG, Grijalva MJ, Powell MR.

Am J Trop Med Hyg. 2001 Aug;65(2):152-8.

PMID:
11508392
20.

Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas' disease.

Waghabi MC, de Souza EM, de Oliveira GM, Keramidas M, Feige JJ, Araújo-Jorge TC, Bailly S.

Antimicrob Agents Chemother. 2009 Nov;53(11):4694-701. doi: 10.1128/AAC.00580-09. Epub 2009 Sep 8.

Supplemental Content

Support Center